 | | Vol. 7.10 – 28 March, 2022 |
| |
|
|
| Researchers induced efficient human pluripotent stem-cell-derived cardiomyocytes maturation through metabolic-pathway modulations and found that peroxisome-proliferator-associated receptor (PPAR) signaling regulated glycolysis and fatty acid oxidation in an isoform-specific manner.
[Cell Stem Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists isolated extracellular vesicles (EVs) from key stages of the human induced pluripotent stem cell-cardiomyocyte differentiation and maturation, with the aim of identifying a promising cell biofactory for EV production, and pinpointed the genetic signatures of bioactive EVs.
[Advanced Science] |
|
|
|
| Phospholamban (PLN) deletion in human induced pluripotent stem cell-cardiomyocytes enhanced contractility at day 30, but proceeded to a cardiac failure phenotype at day 60, with decreased contractility, mitochondrial damage, and increased reactive oxygen species production.
[Stem Cell Reports] |
|
|
|
| Researchers showed that KDM3A was significantly downregulated in rat ischemia/reperfusion and cellular hypoxia/reoxygenation models. KDM3A knockout exacerbated cardiac dysfunction and cardiomyocytes injury both in vivo and in vitro.
[Communications Biology] |
|
|
|
| Investigators established an in vitro model of alcoholic cardiomyopathy based on human induced pluripotent stem cell-derived cardiomyocytes.
[Cell Death Discovery] |
|
|
|
| The authors investigated the potential benefit of LCZ696, an angiotensin receptor–neprilysin inhibitor against doxorubicin-induced cardiotoxicity in rats and H9c2 cells and determined whether the mechanism underlying any such effects involved its antioxidant activity.
[Scientific Reports] |
| |
|
|
| Treatment of Chkb−/− myocytes with peroxisome proliferator-activated receptor agonists enabled fatty acids to be used for β-oxidation and prevented triacyglyerol accumulation, while simultaneously increasing expression of the compensatory choline kinase alpha isoform, preventing muscle cell injury.
[Nature Communications] |
|
|
|
| Scientists demonstrated the key role of fibroadipogenic progenitors and their cross-talk with muscle cells through a paracrine signaling pathway in fibrosis of human skeletal muscle and identified endothelin as a new druggable target to counteract human muscle fibrosis.
[Journal of Cachexia Sarcopenia and Muscle] |
|
|
|
| Single-cell RNA sequencing and functional assays were performed to demonstrate that pericytes in mouse skeletal muscle lost the capacity to synthesize antioxidants during disuse and recovery.
[Journal of Physiology] |
| |
|
|
| Pannexin-1 on endothelial cells acted as a conduit for ATP release that stimulated macrophage activation via P2X7 receptors and mitochondrial DNA release to increase IL-1β and HMGB1 secretion.
[Nature Communications] |
|
|
|
| Sodium thiosulfate, a drug used for the treatment of cyanide poisoning and calciphylaxis, protected against intimal hyperplasia in a mouse model of arterial restenosis and in human vein segments.
[Ebiomedicine] |
|
|
|
| Researchers investigated the molecular mechanism by which valproic acid inhibited rat vascular smooth muscle cell proliferation.
[Biochemical and Biophysical Research Communications] |
|
|
|
|
| The authors provide detailed insights into the roles of NAD+ along with molecular mechanisms during aging and disease conditions, such as the impacts of age-related NAD+ deficiencies on NAD+-dependent enzymes, including poly (ADP-ribose) polymerase, CD38, and sirtuins within skeletal muscle.
[Molecular and Cellular Biochemistry] |
|
|
|
| Investigators provide a brief overview of protocols that have laid the foundation for derivation of stem-cell derived 3D cardiac models.
[BMC Cardiovascular Disorders] |
|
|
|
|
| Capricor Therapeutics announced that its Phase II INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 as a potential treatment option for hospitalized patients with advanced symptoms of COVID-19 met its primary objective of safety.
[Capricor Therapeutics] |
|
|
|
|
| May 9 – 12, 2022
Montreal, Quebec, Canada |
|
|
|
|
|
| | University of California, San Diego – La Jolla, California, United States |
|
|
|
| | Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| | Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| NIH National Institute on Aging – Baltimore, Maryland, United States |
|
|
|
| | Gilead Sciences – Foster City, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
